b777x model
2025-01-13 2025 European Cup b777x model
News
Gift guide: Game changers for building fires, printing photos or watching birds
nn777 legit or not
。
Mic Crenshaw, Progressive MC And Hip-Hop Ambassador Has A New Single, "Ready" Featuring Kiloriti Maasai and Toni Hill
BETHUNE-COOKMAN 79, NORTH DAKOTA 67Cerity Partners LLC trimmed its holdings in Invesco Russell 1000 Dynamic Multifactor ETF ( BATS:OMFL – Free Report ) by 19.2% in the third quarter, Holdings Channel reports. The institutional investor owned 71,884 shares of the company’s stock after selling 17,082 shares during the quarter. Cerity Partners LLC’s holdings in Invesco Russell 1000 Dynamic Multifactor ETF were worth $3,809,000 as of its most recent filing with the Securities and Exchange Commission. Other hedge funds and other institutional investors have also bought and sold shares of the company. Balentine LLC grew its position in shares of Invesco Russell 1000 Dynamic Multifactor ETF by 20.5% in the third quarter. Balentine LLC now owns 5,667,538 shares of the company’s stock valued at $300,323,000 after purchasing an additional 964,398 shares in the last quarter. Arizona PSPRS Trust bought a new position in Invesco Russell 1000 Dynamic Multifactor ETF in the 2nd quarter worth about $281,479,000. Bank of New York Mellon Corp grew its holdings in Invesco Russell 1000 Dynamic Multifactor ETF by 4.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 3,062,504 shares of the company’s stock valued at $160,751,000 after buying an additional 134,468 shares in the last quarter. Orrstown Financial Services Inc. lifted its holdings in shares of Invesco Russell 1000 Dynamic Multifactor ETF by 15.1% in the third quarter. Orrstown Financial Services Inc. now owns 951,524 shares of the company’s stock worth $50,421,000 after buying an additional 125,123 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. boosted its position in shares of Invesco Russell 1000 Dynamic Multifactor ETF by 2.2% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 746,708 shares of the company’s stock valued at $39,195,000 after acquiring an additional 16,361 shares during the period. Invesco Russell 1000 Dynamic Multifactor ETF Stock Up 0.6 % Invesco Russell 1000 Dynamic Multifactor ETF stock opened at $55.58 on Friday. The company has a market cap of $6.51 billion, a price-to-earnings ratio of 21.45 and a beta of 0.94. The business’s fifty day moving average price is $53.77 and its 200 day moving average price is $52.50. Invesco Russell 1000 Dynamic Multifactor ETF Cuts Dividend Invesco Russell 1000 Dynamic Multifactor ETF Company Profile ( Free Report ) The Invesco Russell 1000 Dynamic Multifactor ETF (OMFL) is an exchange-traded fund that mostly invests in large cap equity. The fund tracks an index of US large-cap stocks selected by a combination of five investment factors, which are weighted based on current macroeconomic conditions. OMFL was launched on Nov 8, 2017 and is managed by Invesco. Recommended Stories Want to see what other hedge funds are holding OMFL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Invesco Russell 1000 Dynamic Multifactor ETF ( BATS:OMFL – Free Report ). Receive News & Ratings for Invesco Russell 1000 Dynamic Multifactor ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invesco Russell 1000 Dynamic Multifactor ETF and related companies with MarketBeat.com's FREE daily email newsletter .
American and European stock markets mostly rose on Wednesday after inflation data cemented expectations that the US Federal Reserve will trim interest rates next month. While the Dow fell slightly, the other two major US indices advanced, led by the tech-rich Nasdaq, which piled on almost two percent to close above 20,000 points for the first time. The consumer price index (CPI) rose to 2.7 percent last month from a year ago, up slightly from 2.6 percent in October. "With the CPI numbers broadly in line, it is likely that the Fed will not be derailed and will cut rates again next week," Jochen Stanzl, chief market analyst at CMC Markets. "The data is not a showstopper for the current bull run on Wall Street," he added. Ahead of the data, investors priced in an 86 percent chance the Fed will cut interest rates next week by a quarter percentage point. That rose to more than 98 percent after the CPI data was published. Stocks in Paris and Frankfurt rose ahead of the European Central Bank's own interest rate announcement on Thursday, with analysts expecting another cut as it seeks to boost eurozone growth. Investors are also eyeing political developments in France, where officials said President Emmanuel Macron aims to name a new prime minister "within 48 hours" as he seeks to end political deadlock following the ouster of Michel Barnier. In company news, shares in German retail giant Zalando shed more than four percent on Frankfurt's DAX index, after it acquired domestic rival About You in a deal worth around 1.1 billion euros ($1.2 billion). Shares in Zara owner Inditex slid more than six percent after a record quarterly profit for the group fell short of market estimates. Among US companies, Google parent Alphabet earned 5.5 percent as it announced the launch of Gemini 2.0, its most advanced artificial intelligence model to date. That added to gains after Google also announced Tuesday details of a breakthrough quantum chip. Shares in Shanghai rose but Hong Kong gave up an early rally to end in the red. Traders were keeping tabs on China to see if it will announce further measures to support its struggling economy as leaders were to gather Wednesday for a conference to hammer out next year's agenda. President Xi Jinping and other top leaders on Monday announced their first major shift in policy for more than a decade, saying they would "implement a more active fiscal policy and an appropriately relaxed" strategy. Those remarks sparked hopes for more interest rate cuts and the freeing up of more cash for lending. New York - Dow: DOWN 0.2 percent at 44,148.56 (close) New York - S&P 500: UP 0.8 percent at 6,084.19 (close) New York - Nasdaq Composite: UP 1.8 percent at 20,034.89 (close) London - FTSE 100: UP 0.3 percent at 8,301.62 (close) Paris - CAC 40: UP 0.4 percent at 7,423.40 (close) Frankfurt - DAX: UP 0.3 percent at 20,399.16 (close) Tokyo - Nikkei 225: FLAT at 39,372.23 (close) Hong Kong - Hang Seng Index: DOWN 0.8 percent at 20,155.05 (close) Shanghai - Composite: UP 0.3 percent at 3,432.49 (close) Euro/dollar: DOWN at $1.0498 from $1.0527 on Tuesday Pound/dollar: DOWN at $1.2752 from $1.2771 Dollar/yen: UP at 152.40 yen from 151.95 yen Euro/pound: DOWN at 82.31 from 82.42 pence Brent North Sea Crude: UP 1.8 percent at $73.52 per barrel West Texas Intermediate: UP 2.4 percent at $70.29 per barrel burs-jmb/mlmImpartner Partner Relationship Management platform now available in the Microsoft Azure Marketplace
T-cell malignancies account for about 10-15% of all lymphoid malignancies, and their treatment often involves chemotherapy, immunotherapy, or stem cell transplantation. These cancers can be particularly challenging due to their heterogeneity and resistance to traditional treatments. LAS VEGAS , Dec. 11, 2024 /PRNewswire/ -- T-cell malignancies are a group of cancers originating from the T-cells, a vital part of the immune system responsible for recognizing and combating foreign invaders. These cancers can develop when T-cells undergo genetic mutations, leading to uncontrolled growth and division. T-cell malignancies are generally categorized into two broad types: T-cell lymphomas and T-cell leukemias. T-cell lymphomas primarily affect the lymphatic system, involving lymph nodes and other lymphoid tissues, while T-cell leukemias impact the blood and bone marrow. These malignancies are often more aggressive and harder to treat than B-cell cancers due to their complex biology and resistance to conventional therapies. Symptoms can vary but typically include enlarged lymph nodes, fever, night sweats, and weight loss. Treatment options include chemotherapy, radiation therapy, and novel therapies like CAR T-cell therapy and targeted therapies, which are advancing the understanding and management of these challenging cancers. DelveInsight has recently released a series of epidemiology-based market reports focusing on T-cell malignancies including Acute Lymphoblastic Leukemia, Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma, Anaplastic Large Cell Lymphoma, and Adult T-cell Leukemia/Lymphoma . These reports include a comprehensive understanding of current treatment practices, historical and forecasted patient pool, emerging drugs, market share of individual therapies, and historical and forecasted market size from 2020 to 2034 segmented into 7MM [ the United States , the EU-4 ( Italy , Spain , France , and Germany ), the United Kingdom , and Japan ]. Additionally, the reports feature exhaustive analysis of prominent companies working with their emerging candidates in different stages of clinical development. Let's deep dive into the assessment of these T-cell malignancies markets individually. Acute Lymphocytic Leukemia Market Acute lymphocytic leukemia (ALL), also called acute lymphoblastic leukemia, is a cancer that develops in the blood and bone marrow. It originates from immature white blood cells known as lymphocytes in the bone marrow and is marked by the excessive production of immature cells, referred to as lymphoblasts or leukemic blasts. As the bone marrow fails to produce sufficient red blood cells, healthy white blood cells, and platelets, individuals with ALL are more prone to anemia, frequent infections, and easy bruising or bleeding. Among the 7MM, the US accounted for the highest number of incident cases of acute lymphocytic leukemia. The total incident cases of acute lymphocytic leukemia in the US comprised approximately 6,800 cases in 2023 and are projected to increase during the forecast period. Among the type-specific cases of acute lymphocytic leukemia, B-acute lymphocytic leukemia accounted for nearly 85% of the cases, while T-acute lymphocytic leukemia accounted for nearly 15% in the US. The treatment paradigms of acute lymphocytic leukemia have been revolutionized with the advent of tyrosine kinase inhibitors targeting BCR-ABL1 (GLEEVEC [imatinib mesylate], SPRYCEL [dasatinib], and ICLUSIG [ponatinib]), monoclonal antibodies targeting CD20 (RITUXAN), antibody-drug conjugates targeting CD22 (BESPONSA), bispecific antibodies (BLINCYTO), CD19 chimeric antigen receptor T cell therapy (KYMRIAH and TECARTUS) , and others. As per DelveInsight analysis, in 2023, the market size for acute lymphocytic leukemia across the 7MM was around USD 1.6 billion , with projections indicating further growth by 2034. The United States dominated the market in 2023, contributing approximately USD 1.2 billion . ALL presents a significant market opportunity, with BLINCYTO currently leading the segment. Amgen continues to drive innovation in ALL through its BiTE Technology, receiving FDA approval in June 2024 . Additionally, Amgen is advancing a registration-enabling study to develop a subcutaneous injection formulation of blinatumomab. Acute Lymphocytic Leukemia Pipeline Therapies and Companies Orca-T: Orca Biosystems AUTO1/22: Autolus Therapeutics VENCLEXTA/VENCLYXTO (venetoclax): AbbVie and Roche (Genentech) Daratumumab: J&J Innovative Medicine IMBRUVICA (ibrutinib): Pharmacyclics (an AbbVie Company) JAKAFI (ruxolitinib): Incyte Corporation/Novartis VYXEOS (CPX-351): Jazz Pharmaceuticals Obecabtagene autoleucel (obe-cel): Autolus Therapeutics SNDX-5613 (revumenib): Syndax Pharmaceuticals UCART22: Cellectis ADCT-602: ADC Therapeutics WU-CART-007: Wugen For a comprehensive view of the acute lymphocytic leukemia market, check out the Acute Lymphocytic Leukemia Market Assessment Peripheral T-cell Lymphoma Market Peripheral T-cell lymphoma represents a heterogeneous collection of aggressive lymphomas arising from mature T-cells and natural killer cells, comprising approximately 10–15% of all non-Hodgkin lymphomas globally. PTCL is more prevalent in Asia compared to North America and Europe . PTCL has been reported to account for 25% of all NHL cases in Japan . The increased rate of T-cell lymphomas in Asia is attributed to the low incidence of follicular lymphomas. The total incident cases of PTCL in the 7MM were 26,000 cases in 2023; these cases are estimated to increase by 2034. As more targetable mutations are identified and new targeted therapies are developed, the range of treatment options for patients and oncologists continues to expand. However, with the rapid pace of drug approvals, it is crucial to ensure that adequate supporting data justifies the use of specific therapies in the appropriate treatment settings, whether as adjuvant, consolidation, first-line, or subsequent treatments. Peripheral T-cell lymphoma remains a significant therapeutic challenge due to its aggressive nature, rarity, and high heterogeneity. Conventional chemotherapy for PTCL typically involves anthracycline-based regimens (such as CHOP and EPOCH) or non-anthracycline alternatives (including platinum, etoposide, gemcitabine, and methylprednisolone). While the majority of patients initially undergo chemotherapy, nearly a quarter develop primary refractory disease. Many others relapse even after responding to induction chemotherapy, with a median overall survival of just six months. According to NCCN guidelines, specific PTCL subtypes are also treated with six cycles of CHOP-21 or CHOEP, often combined with involved-site radiation therapy. The FDA has approved several drugs for PTCL treatment, including BELEODAQ (Belinostat, Acrotech Biopharma), ISTODAX (Romidepsin, Celgene), FOLOTYN (Pralatrexate, Acrotech Biopharma), ARRANON (Nelarabine, GlaxoSmithKline), XALKORI (Crizotinib, Pfizer), and ADCETRIS (Brentuximab Vedotin, Seattle Genetics). Until recently, there was no established standard of care for first-line treatment in PTCL, leaving a significant gap in approved therapies. The approval of ADCETRIS in November 2018 by the US FDA has transformed the treatment landscape. ADCETRIS, in combination with chemotherapy, is now the first and only FDA-approved regimen for first-line treatment of adults with previously untreated systemic ALCL or other CD30-expressing PTCL. Notably, its approval came less than two weeks after submission under the FDA's real-time oncology review pilot program. Key players, such as Secura Bio, HUYA Bioscience International, Verastem, Solasia Pharma, Seagen, Dizal Pharmaceutical , and others, are evaluating their lead candidates in different stages of clinical development, respectively. As per the DelveInsight assessment, the total market size in the 7MM for PTCL was estimated to be ~USD 680 million in 2020, which is projected to show positive growth by 2034. This growth of the PTCL market is expected to be mainly driven by increased diagnosed incidence, patient awareness, and a robust clinical pipeline during the forecast period (2024–2034). PTCL Pipeline Therapies and Companies COPIKTRA (duvelisib): Secura Bio Linperlisib (YY-20394): Shanghai YingLi Pharmaceutical Golidocitinib (DZD4205) : Dizal Pharmaceuticals Nanatinostat + Valganciclovir: Viracta Therapeutics Lacutamab/IPH4102: Innate Pharma Sugemalimab (CS1001): CStone Pharmaceuticals AFM13: Affimed Tolinapant (ASTX660): Otsuka Pharmaceutical/Astex Pharmaceuticals AUTO4: Autolus MT-101: Myeloid Therapeutics KEYTRUDA (pembrolizumab): Merck Sharp & Dohme OPDIVO (nivolumab): Bristol Myers Squibb To gain a deeper understanding of the PTCL market, be sure to explore the Peripheral T-cell Lymphoma Market Outlook Cutaneous T-cell Lymphoma Market Cutaneous T-cell lymphomas are rare cancers that predominantly involve the skin. Some types progress slowly within the skin, while others may spread to the blood or lymph nodes. The most prevalent form of CTCL is mycosis fungoides, along with its leukemic variant, Sézary syndrome. Another frequently encountered group includes CD30-positive lymphoproliferative disorders (CD30+ LPDs). In 7MM, the United States accounted for the highest number of incident cases of CTCL, which is 46% of the total incident population of CTCL in 7MM in 2023, as per DelveInsight. In the US, out of all stage-specific cases of CTCL, Stage-IA accounted for the highest number of cases, followed by Stage-IB and Stage-IIB cases in 2023. There is currently no approved first-line therapy for early-stage (I–IIA) cutaneous T-cell lymphoma, highlighting a significant unmet need in this patient population. Treatment decisions for patients with mycosis fungoides and Sézary syndrome, both types of CTCL, are influenced by factors such as the extent of skin involvement, the type of lesions, and whether metastasis is present. Therapies for mycosis fungoides focus on either localized skin treatment or systemic approaches, allowing many patients to achieve long-term remission and maintain normal lives. In contrast, Sézary syndrome, marked by systemic involvement, often requires systemic therapies, either alone or in combination, to improve long-term outcomes. TARGRETIN, ADCETRIS, POTELIGEO, ZOLINZA, and ISTODAX are approved by the US FDA for the treatment of Mycosis Fungoides and Sezary Syndrome. Other systemic therapies such as interferons (alfa and gamma), methotrexate, and other retinoids (acitretin and isotretinoin) also offer clinical benefits but have only been evaluated in small studies. As per DelveInsight analysis, the market size of CTCL in the 7MM is expected to cross USD 780 million by 2034. This growth is mainly driven by advancements in targeted therapies, rising awareness of rare cancers, and increasing research and development investments. The adoption of innovative treatments such as monoclonal antibodies and checkpoint inhibitors, coupled with improved diagnostic technologies, is anticipated to enhance market expansion. Additionally, a growing patient population and supportive regulatory policies will further bolster market growth. CTCL Pipeline Therapies and Companies HyBryte (SGX301): Soligenix KINSELBY (resminostat): 4SC AG Lacutamab: Innate Pharma Explore in-depth for a comprehensive understanding of the Cutaneous T-cell Lymphoma Clinical Trials Anaplastic Large Cell Lymphoma Market Anaplastic large cell lymphoma (ALCL) is a rare subtype of non-Hodgkin lymphoma, characterized by large, irregular lymphoid cells that express the CD30 antigen. ALCL accounts for approximately 1% of all NHL cases and 16% of T-cell lymphomas. ALK-positive ALCL is associated with conditions such as HIV, mycosis fungoides, and pulmonary or inflammatory pseudotumors. In contrast, ALK-negative ALCL is more commonly observed in older individuals and is frequently linked to extranodal disease involvement. As per DelveInsight's analysis, ALCL has a slightly higher incidence in men compared to women. ALK-positive ALCL typically affects children and adolescents, with a median age of 30 years, while ALK-negative ALCL tends to affect older adults, with a median age of 54 years. ALK-positive ALCL carries a better prognosis, with 5-year survival rates of 70% to 90% , compared to 40% to 60% for ALK-negative ALCL. The treatment of ALCL varies based on its subtype and stage. Systemic ALCL is commonly addressed with chemotherapy regimens such as CHOP or CHOEP, showing improved outcomes in ALK-positive cases. The key drugs used for the treatment of anaplastic large cell lymphoma are – Pfizer's XALKORI and Takeda's ADCETRIS. For relapsed or refractory cases, brentuximab vedotin has proven effective. Primary cutaneous ALCL is typically managed through radiation, surgery, or chemotherapy and generally has a good prognosis. Breast implant-associated ALCL is treated by removing the implant, with radiation or chemotherapy added if the disease has spread. The ALCL market is anticipated to witness a substantial positive shift owing to better uptake of existing drugs, the expected market launch of therapies, and raised awareness. Additionally, the ALCL market size is expected to increase due to an increasing diagnosed prevalent population, awareness about the subtype of ALCL (Breast implant-associated ALCL), and an increase in R&D activity, which would essentially boost the commercial success of emerging therapies. Anaplastic Large Cell Lymphoma Pipeline Therapies and Companies AUTO4: Autolus Therapeutics SGN-35T: Seagen To access a complete analysis of the anaplastic large cell lymphoma market, visit Anaplastic Large Cell Lymphoma Market Assessment Adult T-cell Leukemia/Lymphoma Market Adult T-cell Leukemia/Lymphoma (ATLL) is a rare and aggressive malignancy of mature T lymphocytes caused by infection with the human T-cell lymphotropic virus type 1 (HTLV-1). ATLL is classified into four clinical subtypes: acute, lymphomatous, chronic, and smoldering, each with distinct prognoses. The acute and lymphomatous forms are the most aggressive, with a median survival of less than a year without treatment. ATLL commonly affects adults aged 40–60 years and is associated with immunosuppression, hypercalcemia, and frequent involvement of skin, lymph nodes, and bone marrow. The global prevalence varies, but it is estimated that about 5–10% of individuals infected with HTLV-1 develop ATLL after decades of latency. Treatment for ATLL is challenging, as the disease presents with a wide range of clinical manifestations, from chronic to acute forms. First-line therapy often involves combination chemotherapy regimens, such as the CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone) regimen, which has shown effectiveness in treating the aggressive forms of ATLL. For more refractory or relapsed cases, a bone marrow transplant may be considered as a curative option. Additionally, the use of denileukin diftitox, a fusion protein targeting CD25, has been approved for relapsed or refractory ATLL. Newer therapies are exploring the use of targeted agents, including histone deacetylase inhibitors (e.g., romidepsin) and lenalidomide, a potent immune-modulatory drug, to improve outcomes in patients with advanced disease. However, despite these options, ATLL treatment remains an area in urgent need of innovation to improve survival rates and quality of life for patients. The Adult T-cell leukemia/lymphoma market is expected to witness significant growth in the coming years, driven by advancements in diagnostics, therapies, and an increased understanding of the disease. Additionally, innovations in immunotherapies, including monoclonal antibodies, CAR-T cell therapies, and combination regimens, are expected to revolutionize the treatment landscape, offering hope for improved survival rates. Moreover, ongoing research into biomarkers and precision medicine will likely lead to better patient stratification and more effective treatment plans. Overall, the ATLL market is poised for expansion, attracting investments in research and development, clinical trials, and regulatory approvals to meet the growing need for better, more accessible therapies. Adult T-cell Leukemia/Lymphoma Pipeline Therapies and Companies Valemetostat Tosylate: Daiichi Sankyo BEAM-201: Beam Therapeutics Inc. Tolinapant: Astex Pharmaceuticals To delve into the adult T-cell leukemia/lymphoma market landscape in more detail, access the Adult T-cell Leukemia/Lymphoma Market Report Trending Oncology Reports Non-Hodgkin Lymphoma Market Non-Hodgkin Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key Non-Hodgkin lymphoma companies, including Roche, Pfizer, Amgen, Novartis, Teva Pharmaceuticals, Genentech, ACD Therapeutics , among others. Non-Hodgkin Lymphoma Pipeline Non-Hodgkin Lymphoma Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key Non-Hodgkin lymphoma companies, including Roche, Pfizer, Amgen, Novartis, Teva Pharmaceuticals, Genentech, ACD Therapeutics , among others. B-Cell Lymphoma Market B-Cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key B-cell lymphoma companies, including Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc, Shanghai Hengrui Pharmaceutical, BeiGene, Hanmi Pharmaceutical, among others. Diffuse Large B-Cell Lymphoma Market Diffuse Large B-Cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key B-cell lymphoma companies, including AbbVie, Genmab, Merck, Roche, Xencor and Janssen, Denovo Biopharma, Calithera Biosciences, IMV, Biogen, Autolus Therapeutics, Allogene Therapeutics, Novartis, Miltenyi Biomedicine, Regeneron Pharmaceuticals, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur info@delveinsight.com +14699457679 www.delveinsight.com Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpgQuest Partners LLC increased its holdings in QuickLogic Co. ( NASDAQ:QUIK – Free Report ) by 5,067.5% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 10,955 shares of the semiconductor company’s stock after purchasing an additional 10,743 shares during the period. Quest Partners LLC’s holdings in QuickLogic were worth $84,000 as of its most recent filing with the Securities and Exchange Commission. Several other institutional investors and hedge funds also recently bought and sold shares of the business. Cutter & CO Brokerage Inc. bought a new position in QuickLogic in the 3rd quarter worth approximately $106,000. Squarepoint Ops LLC boosted its holdings in QuickLogic by 194.3% in the 2nd quarter. Squarepoint Ops LLC now owns 55,152 shares of the semiconductor company’s stock worth $573,000 after buying an additional 36,409 shares during the period. Marshall Wace LLP boosted its holdings in QuickLogic by 118.4% in the 2nd quarter. Marshall Wace LLP now owns 73,549 shares of the semiconductor company’s stock worth $764,000 after buying an additional 39,878 shares during the period. XTX Topco Ltd bought a new position in QuickLogic in the 2nd quarter worth approximately $127,000. Finally, American Century Companies Inc. boosted its holdings in QuickLogic by 24.8% in the 2nd quarter. American Century Companies Inc. now owns 18,841 shares of the semiconductor company’s stock worth $196,000 after buying an additional 3,750 shares during the period. 31.54% of the stock is owned by institutional investors. QuickLogic Stock Down 1.4 % Shares of NASDAQ:QUIK opened at $7.63 on Friday. The firm has a fifty day moving average price of $7.87 and a two-hundred day moving average price of $9.40. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.12 and a quick ratio of 1.05. QuickLogic Co. has a one year low of $6.75 and a one year high of $20.75. The company has a market cap of $112.21 million, a price-to-earnings ratio of -76.30 and a beta of 1.56. Insider Buying and Selling In other news, CFO Elias Nader sold 4,458 shares of the business’s stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $7.42, for a total value of $33,078.36. Following the completion of the sale, the chief financial officer now directly owns 52,740 shares in the company, valued at approximately $391,330.80. The trade was a 7.79 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink . Also, VP Timothy Saxe sold 10,000 shares of the company’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $6.95, for a total transaction of $69,500.00. Following the completion of the sale, the vice president now directly owns 108,004 shares of the company’s stock, valued at $750,627.80. This trade represents a 8.47 % decrease in their position. The disclosure for this sale can be found here . 2.49% of the stock is owned by company insiders. Wall Street Analyst Weigh In Several research analysts recently commented on the stock. StockNews.com raised shares of QuickLogic to a “sell” rating in a report on Wednesday, November 20th. Oppenheimer cut their price target on shares of QuickLogic from $16.00 to $13.00 and set an “outperform” rating for the company in a report on Wednesday, August 14th. Finally, Craig Hallum cut their price target on shares of QuickLogic from $12.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday, November 12th. Get Our Latest Analysis on QuickLogic About QuickLogic ( Free Report ) QuickLogic Corporation operates as a fabless semiconductor company in the United States. The company offers embedded FPGA intellectual property, low power, multicore semiconductor system-on-chips, discrete FPGAs, and AI software; and end-to-end artificial intelligence/machine learning solution with accurate sensor algorithms using AI technology. Read More Want to see what other hedge funds are holding QUIK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for QuickLogic Co. ( NASDAQ:QUIK – Free Report ). Receive News & Ratings for QuickLogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for QuickLogic and related companies with MarketBeat.com's FREE daily email newsletter .
Join this golf club and you’ll get 7 ‘home’ courses across the USImprisoned conman Sukesh Chandrashekhar, who is currently incarcerated at Delhi's Tihar Jail, has once again made headlines with his Christmas letter to Bollywood actress Jacqueline Fernandez . This letter, which has quickly gone viral on social media, comes as part of a series of personal messages Sukesh has written to Jacqueline during his time in custody. ET Year-end Special Reads Corporate Kalesh: Top family disputes of India Inc in 2024 The world of business lost these eminent people in 2024 Fast, faster, fastest: How 2024 put more speed into your shopping An Extravagant Christmas Gift For Jacqueline Fernandez In his Christmas letter, Sukesh expresses deep affection for Jacqueline and reveals an extravagant gift he plans to give her. He writes, “Baby girl, Merry Christmas. Another beautiful year and most favourite festival is passing without our love and togetherness. Our souls are connected. When I wish you a Merry Christmas, I am able to hold both our hands and look into your eyes.” This heartfelt message is just the beginning of his bold gesture, which has captivated social media users and fueled curiosity about their relationship. Sukesh goes on to promise an unexpected gift: “Today, I am gifting you not a bottle of wine but an entire vineyard in the country of love 'France', which you never even dreamed of.” The vineyard he refers to is a 107-year-old estate, complete with a stunning Tuscan-style house. The conman adds that he envisions walking through the vineyard hand-in-hand with Jacqueline, further deepening the intrigue surrounding their connection. “I am desperate to take a walk in this garden holding your hand. The world may think that I am crazy, but I am really crazy in love with you. Wait till I come out, then the whole world will see us together,” he writes, emphasizing the strength of his feelings. Previous Letters and Declarations of Love This isn't the first time Sukesh has penned a letter to Jacqueline. Earlier this year, he wrote to her on his birthday, expressing how much he missed her and how priceless her love was to him. He wrote, “You and your love is the bestest gift which is priceless in my life, you know I am here for you standing by you come what may. Love you my baby, thank you for giving me your heart. I also thank all my supporters and friends, for all your wishes on my birthday. I have received hundreds of letters, greetings. I feel blessed, thank you." In addition to this, Sukesh also wished Jacqueline a Happy Holi in another letter, in which he assured her that he would restore all the colors that had faded or disappeared. These letters, filled with declarations of love and extravagant promises, have continued to fuel speculation about the nature of their relationship. While Sukesh claims they are romantically involved, Jacqueline has denied these allegations. Sukesh’s Criminal Background and Media Attention Sukesh's criminal activities, particularly his involvement in a Rs 200 crore money laundering case, have kept him in the public eye. He was arrested for duping Malvinder Singh's wife and posing as high-ranking government officials to extort money. The Enforcement Directorate (ED) has summoned Jacqueline and other individuals like Nora Fatehi for questioning in connection with the extortion case. Despite the serious nature of his crimes, Sukesh has managed to stay relevant through his constant public communications from prison, which only intensifies the media’s curiosity about his relationship with Jacqueline. Aside from the extortion case, Sukesh is also accused of bribing Election Commission officials to secure a political symbol for the VK Sasikala faction of the AIADMK. Facing charges under the Prevention of Money Laundering Act (PMLA), Sukesh remains a polarizing figure in the media.
What's the outlook for ASX dividend shares in 2025?Customers from one of Australia’s biggest banks are being locked out of internet banking. ING Australia confirmed in a post to X that customers had reported issues with the banking app and website on Wednesday morning. “We are aware that some customers are currently experiencing issues accessing the ING app and website,” the post read. “Our teams are investigating this issue and we will provide further updates shortly. “We are extremely sorry to any customers who have been impacted.” Customers first began reporting issues with DownDetector at 7.30am. Disgruntled customers took to social media to air their grievances with the major bank following the most recent outage on Wednesday. “Looks like I’m not buying anything this morning. Come on guys not good enough,” one person wrote to X. “AGAIN!!! this happened 2-3 weeks ago as well..” another wrote. “No worries guys, just waiting to transfer money so we can get our car back from being serviced this morning, we’ll just walk everywhere instead. Useless,” added another. The outage comes just four weeks after customers were hit with another outage. ING Australia customers reported being unable to access the website or banking app about 9am on Wednesday, October 30. At its peak, more than 2300 people reported issues accessing ING Australia banking services. Originally published as Major outage hits ING Australia customers just weeks after last disaster
Andrew met the individual through “official channels” with “nothing of a sensitive nature ever discussed”, a statement from his office said. The businessman – known only as H6 – lost an appeal over a decision to bar him from entering the UK on national security grounds. He brought a case to the Special Immigration Appeals Commission (SIAC) after then-home secretary Suella Braverman said he should be excluded from the UK in March 2023. H6 was described as a “close confidante” of The Duke. Judges were told that in a briefing for the home secretary in July 2023, officials claimed H6 had been in a position to generate relationships between prominent UK figures and senior Chinese officials “that could be leveraged for political interference purposes”. They also said that H6 had downplayed his relationship with the Chinese state, which combined with his relationship with Andrew, 64, represented a threat to national security. A statement from Andrew’s office said: “The Duke of York followed advice from His Majesty’s Government and ceased all contact with the individual after concerns were raised. “The Duke met the individual through official channels with nothing of a sensitive nature ever discussed. “He is unable to comment further on matters relating to national security.” At a hearing in July, the specialist tribunal heard that the businessman was told by an adviser to Andrew that he could act on the duke’s behalf when dealing with potential investors in China, and that H6 had been invited to Andrew’s birthday party in 2020. A letter referencing the birthday party from the adviser, Dominic Hampshire, was discovered on H6’s devices when he was stopped at a port in November 2021. In a ruling on Thursday, Mr Justice Bourne, Judge Stephen Smith and Sir Stewart Eldon, dismissed the challenge.Taylor Swift makes surprise visit to Kansas City children’s hospital
Reilly scores 18 as Delaware downs Rider 72-66
The Indiana Pacers will acquire center Thomas Bryant in an upcoming trade with the Miami Heat, ESPN's Shams Charania reported on Friday. The deal will involve a second-round pick swap, per Charania. Bryant is playing on a one-year, $2 million contract and becomes eligible for a trade on Sunday. Appearing in 10 games so far this season, Bryant has averaged 4.1 points in 11.5 minutes per night while serving as a backup to Heat center Bam Adebayo. The trade will help the Heat in the franchise's bid to stay below the second luxury tax apron. The exchange will save the Heat $4.7 million against the tax, leaving them $3.7 million below the second apron, per ESPN's Bobby Marks. The Heat also gained a $2.1 million trade exception by trading Bryant, per Marks. The deal will meanwhile leave the Heat with just 13 roster players. Miami will need to get back to the 14-man minimum within two weeks. The deal meanwhile leaves the Pacers just below the luxury tax, according to Marks. The Pacers have 15 roster players and could make another deal in order to send out some salary. Kevin Love has served as Adebayo's primary backup since the Heat acquired him in a midseason trade with the Cleveland Guardians last campaign. The addition of Kel'el Ware in the 2024 NBA draft added another option behind Love and made Bryant a movable option for a team in need of moving out some salary. Bryant could now get more playing opportunities in Indiana, where the Pacers have been hunting for a backup to play behind Myles Turner since losing Isaiah Jackson and James Wiseman to Achilles injuries. Obi Toppin has been backing up Turner in Jackson and Wiseman's place. Adding Bryant could allow Toppin to return to his true position at forward. The Pacers play on Friday night against the Philadelphia 76ers, but will have to wait until at least Sunday's game against the New Orleans Pelicans to potentially add Bryant to the lineup.